Novozymes Biopharma Joins with GE Healthcare to Produce and Sell Protein A
Novozymes Biopharma UK Ltd. (Nottingham, UK) has signed a license agreement with GE Healthcare Life Sciences (Chalfont St. Giles, UK), which enables Novozymes Biopharma to produce and deliver native, animal-free Protein A using GE Healthcare technology.
Novozymes Biopharma UK Ltd. (Nottingham, UK) has signed a license agreement with GE Healthcare Life Sciences (Chalfont St. Giles, UK), which enables Novozymes Biopharma to produce and deliver native, animal-free Protein A using GE Healthcare technology. Novozymes Biopharma’s Protein A, which is now commercially available, is targeted to customers involved in the production of chromatography media.
Protein A is produced by Novozymes Biopharma AB in Sweden using GE Healthcare’s proprietary technology and production strain. The protein is the active component in chromatography media used in the production of antibodies. Novozymes’ Protein A can then be used to purify antibodies in drug production and biochemical analysis applications.
In nature, the microorganism Staphylococcus aureus uses Protein A to bind antibodies to hide itself from the immune system when invading the body. The ability of Protein A to bind to antibodies has been used successfully at the industrial scale for several years to produce monoclonal antibodies that are used as drugs in the treatment of illnesses such as arthritis and cancer.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
